Highlights
- Market Cap
- $8.19B
- Enterprise Value
- $8.36B
- EPS (TTM)
- $0.52
- PE Ratio
- 100.53
- Total Revenue (TTM)
- $1.22B
- Gross Profit (TTM)
- $792.76M
- EBITDA (TTM)
- $173.06M
- Year Range
- $46.01 - $72.16
- Target Price
- $68.75
- ROA (TTM)
- 3.21%
- ROE (TTM)
- 3.99%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Bio-Techne Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Bio-Techne Corporation (TECH) has returned -11.02% so far this year and -10.34% over the past 12 months. Over the last ten years, TECH has returned 8.84% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Bio-Techne Corporation
- 1D
- 0.42%
- 1M
- -11.42%
- YTD
- -11.02%
- 6M
- -5.80%
- 1Y
- -10.34%
- 3Y*
- -10.55%
- 5Y*
- -11.26%
- 10Y*
- 8.84%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Dec 9, 1992, TECH's average daily return is +0.08%, while the average monthly return is +1.48%. At this rate, your investment would double in approximately 3.9 years.
Historically, 55% of months were positive and 45% were negative. The best month was Jun 2000 with a return of +66.4%, while the worst month was Jan 2022 at -27.2%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.
On a daily basis, TECH closed higher 49% of trading days. The best single day was May 1, 2003 with a return of +21.0%, while the worst single day was Oct 24, 2000 at -19.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.98% | -7.82% | -11.42% | -11.02% | |||||||||
| 2025 | 2.11% | -15.94% | -5.05% | -14.12% | -3.72% | 6.30% | 6.38% | -0.03% | 1.83% | 12.48% | 3.24% | -8.84% | -17.89% |
| 2024 | -8.86% | 4.74% | -4.32% | -10.20% | 22.24% | -7.18% | 13.87% | -9.22% | 8.03% | -7.73% | 2.41% | -4.42% | -6.13% |
| 2023 | -3.89% | -8.72% | 2.13% | 7.67% | 2.49% | -0.20% | 2.17% | -5.90% | -13.18% | -19.74% | 15.30% | 22.67% | -6.49% |
| 2022 | -27.24% | 11.51% | 3.25% | -12.32% | -2.53% | -6.25% | 11.15% | -13.80% | -14.41% | 4.32% | 14.87% | -2.48% | -35.69% |
| 2021 | 2.32% | 11.41% | 5.60% | 11.93% | -3.12% | 8.80% | 7.10% | 3.58% | -2.92% | 8.06% | -9.80% | 9.60% | 63.40% |
Benchmark Metrics
Bio-Techne Corporation has an annualized alpha of 13.10%, beta of 0.82, and R² of 0.14 versus S&P 500 Index. Calculated based on daily prices since December 10, 1992.
- This stock captured 112.14% of S&P 500 Index gains but only 90.02% of its losses — a favorable profile for investors.
- R² of 0.14 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.10%
- Beta
- 0.82
- R²
- 0.14
- Upside Capture
- 112.14%
- Downside Capture
- 90.02%
Return for Risk
Risk / Return Rank
TECH ranks 29 for risk / return — below 29% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Bio-Techne Corporation (TECH) and compare them to a chosen benchmark (S&P 500 Index).
| TECH | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.23 | 0.90 | -1.13 |
Sortino ratioReturn per unit of downside risk | -0.04 | 1.39 | -1.42 |
Omega ratioGain probability vs. loss probability | 1.00 | 1.21 | -0.22 |
Calmar ratioReturn relative to maximum drawdown | -0.33 | 1.40 | -1.73 |
Martin ratioReturn relative to average drawdown | -0.81 | 6.61 | -7.41 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore TECH risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Bio-Techne Corporation provided a 0.61% dividend yield over the last twelve months, with an annual payout of $0.32 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.32 | $0.32 | $0.40 | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 |
Dividend yield | 0.61% | 0.54% | 0.56% | 0.41% | 0.39% | 0.25% | 0.40% | 0.58% | 0.88% | 0.99% | 1.24% | 1.42% |
Monthly Dividends
The table displays the monthly dividend distributions for Bio-Techne Corporation. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.08 | $0.00 | $0.08 | |||||||||
| 2025 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.32 |
| 2024 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.16 | $0.00 | $0.40 |
| 2023 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.32 |
| 2022 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.32 |
| 2021 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.08 | $0.00 | $0.32 |
Dividend Yield & Payout
Dividend Yield
Bio-Techne Corporation has a dividend yield of 0.61%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Bio-Techne Corporation has a payout ratio of 61.50%, which is quite average when compared to the overall market. This suggests that Bio-Techne Corporation strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bio-Techne Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bio-Techne Corporation was 74.39%, occurring on Apr 7, 2003. Recovery took 1283 trading sessions.
The current Bio-Techne Corporation drawdown is 60.38%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -74.39% | Jul 5, 2000 | 691 | Apr 7, 2003 | 1283 | May 12, 2008 | 1974 |
| -64.78% | Sep 27, 2021 | 917 | May 21, 2025 | — | — | — |
| -52.7% | Feb 4, 1993 | 379 | Aug 4, 1994 | 264 | Aug 21, 1995 | 643 |
| -43.8% | Aug 11, 2008 | 145 | Mar 9, 2009 | 543 | May 3, 2011 | 688 |
| -38.75% | Mar 23, 1998 | 113 | Aug 31, 1998 | 77 | Dec 18, 1998 | 190 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bio-Techne Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Bio-Techne Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TECH, comparing it with other companies in the Biotechnology industry. Currently, TECH has a P/E ratio of 100.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TECH relative to other companies in the Biotechnology industry. Currently, TECH has a P/S ratio of 6.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TECH in comparison with other companies in the Biotechnology industry. Currently, TECH has a P/B value of 4.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |